- Home
- AAMI vs RXST Comparison
AAMI vs RXST Comparison
Compare AAMI & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- RXST
- Stock Information
- Founded
- AAMI 1980
- RXST 1997
- Country
- AAMI United States
- RXST United States
- Employees
- AAMI N/A
- RXST N/A
- Industry
- AAMI Investment Managers
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AAMI Finance
- RXST Health Care
- Exchange
- AAMI Nasdaq
- RXST Nasdaq
- Market Cap
- AAMI 1.1B
- RXST 1.0B
- IPO Year
- AAMI N/A
- RXST 2021
- Fundamental
- Price
- AAMI $30.49
- RXST $15.04
- Analyst Decision
- AAMI Hold
- RXST Buy
- Analyst Count
- AAMI 2
- RXST 10
- Target Price
- AAMI $27.00
- RXST $39.30
- AVG Volume (30 Days)
- AAMI 246.6K
- RXST 943.0K
- Earning Date
- AAMI 07-31-2025
- RXST 05-07-2025
- Dividend Yield
- AAMI 0.13%
- RXST N/A
- EPS Growth
- AAMI 46.05
- RXST N/A
- EPS
- AAMI 2.40
- RXST N/A
- Revenue
- AAMI $519,799,999.00
- RXST $148,310,000.00
- Revenue This Year
- AAMI $5.28
- RXST $22.25
- Revenue Next Year
- AAMI $6.24
- RXST $18.58
- P/E Ratio
- AAMI $12.53
- RXST N/A
- Revenue Growth
- AAMI 18.00
- RXST 46.70
- 52 Week Low
- AAMI $21.45
- RXST $12.53
- 52 Week High
- AAMI $31.52
- RXST $60.81
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- RXST 45.75
- Support Level
- AAMI N/A
- RXST $14.70
- Resistance Level
- AAMI N/A
- RXST $16.36
- Average True Range (ATR)
- AAMI 0.00
- RXST 0.84
- MACD
- AAMI 0.00
- RXST 0.09
- Stochastic Oscillator
- AAMI 0.00
- RXST 16.67
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.